Clinical Trials Browser

Phase 1 × INDUSTRY × CYC065 × Clear all

NCT04017546 2024-09-19

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02552953 2024-05-31

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Phase 1 Completed

Neoplasms

NCT03739554 2024-01-25

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Phase 1 Completed

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell